Pathstone Holdings
ELDN icon

Pathstone Holdings’s Eledon Pharmaceuticals ELDN Stock Holding History

Pathstone Holdings’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,464
Closed -$79.8K – 2355
2025
Q2 		$79.8K Sell
29,464
-10,350
-26% -$31.1K ﹤0.01% 2132
2025
Q1 		$135K Hold
39,814
– – ﹤0.01% 2128
2024
Q4 		$164K Buy
39,814
+26,785
+206% +$106K ﹤0.01% 2198
2024
Q3 		$32.4K Hold
13,029
– – ﹤0.01% 2306
2024
Q2 		$34.4K Hold
13,029
– – ﹤0.01% 2278
2024
Q1 		$26.8K Hold
13,029
– – ﹤0.01% 2279
2023
Q4 		$23.5K Buy
+13,029
New +$18.1K ﹤0.01% 2186

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Pathstone Holdings's ELDN Position: Q3 2025 in Review

Pathstone Holdings sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 29,464 shares — an estimated $79.8K sold.

Pathstone Holdings first reported a position in ELDN in Q4 2023 and held it in 7 quarters. The position peaked at $164K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Pathstone Holdings reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Pathstone Holdings sold 29,464 Eledon Pharmaceuticals shares in Q3 2025, an estimated $79.8K.
  • Pathstone Holdings first reported a position in Eledon Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Pathstone Holdings's Eledon Pharmaceuticals position peaked at $164K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Pathstone Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.